FRANKLIN LAKES, N.J.,
July 23, 2019 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today issued its 2018 Sustainability
Report, focusing on management of the environmental, social and
governance factors that support the company's 2020 Sustainability
Goals.
BD's sustainability strategy is driven by its purpose –
Advancing the world of health™ – and focuses on four
priorities that are most relevant to the business and its
stakeholders:
- Innovation – health care safety, outcomes and cost
- Access – health care in resource-limited
populations
- Efficiency – environmentally sound products and
resilient operations
- Empowerment – positive workforce and community
impacts
"BD's 2020 sustainability goals reflect our commitment to the
role we play in finding solutions to complex global issues in
partnership with our employees, customers and stakeholders," said
Vincent A. Forlenza, chairman and
CEO. "We are pleased with the progress we have made toward our
goals and believe there are opportunities ahead to make a real
difference as we work to address global challenges such as climate
change and antimicrobial resistance."
Highlights from this year's report include:
- Innovation: In 2018, BD launched more than 20 new
products, demonstrating a continued focus on innovation in key
areas, including medication management, lab automation and health
care worker and patient safety. The company continues to pursue and
invest in new digital technologies to enhance product and solution
offerings and is focused on collaboration across the industry to
enhance cybersecurity of medical technology and devices.
- Access: In 2018, the company celebrated a decade of
partnership with the U.S. President's Emergency Plan for AIDS
Relief (PEPFAR) and U.S. Centers for Disease Control (CDC) through
its Labs for Life collaboration, which focuses on strengthening
laboratory systems and upgrading clinical practices in phlebotomy,
infusion and injection. BD also expanded its existing partnership
with the United States Agency for International Development (USAID)
to address drug-resistant tuberculous in select high-burden
countries.
- Efficiency: BD continues to work across the value chain
to improve environmental performance and the resiliency of its
global operations. The company's commitment to on-site generation
and renewable energy enabled a continued reduction in greenhouse
gas emissions in 2018 (down 75% from baseline year of 2008,
normalized to cost of products sold). BD continues to find
opportunities to address water consumption and waste generation,
seeing continued improvements against its 2020 targets in both
areas (47% and 33% reduction respectively, from baseline year of
2008, normalized to cost of products sold), despite increases in
production.
- Empowerment: BD is committed to fostering an environment
that welcomes and empowers an inclusive and diverse workforce which
has earned the company recognition by a number of organizations in
2018, including the Human Rights Campaign Foundation (Best Place to
Work for LGBTQ Equality). The company continues to place a strong
focus on philanthropy, providing $9.9
million in cash donations and $6.4
million in product donations, as well as expertise and
employee volunteer hours to non-profit organizations around the
world.
New to this year's report, BD spotlights three global challenge
areas – human rights, climate change, antimicrobial resistance –
and details how these topics intersect with work across the four
key priorities of the company's sustainability strategy.
For more information about the company's sustainability
goals, view the 2018 Sustainability Report here:
https://www.bd.com/en-us/company/sustainability-at-bd.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 65,000 employees have a passion and
commitment to help enhance the safety and efficiency of clinicians'
care delivery process, enable laboratory scientists to accurately
detect disease and advance researchers' capabilities to develop the
next generation of diagnostics and therapeutics. BD has a presence
in virtually every country and partners with organizations around
the world to address some of the most challenging global health
issues. By working in close collaboration with customers, BD can
help enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. For more information on
BD, please visit bd.com.
Contacts:
|
|
|
|
Jessica
Offerjost
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
201.847.5297
|
201.847.5378
|
Jessica.Offerjost@bd.com
|
Monique_Dolecki@bd.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-releases-2018-sustainability-report-300889048.html
SOURCE BD (Becton, Dickinson and Company)